Cargando…

Epoprostenol‐associated ascites in pulmonary arterial hypertension

The development of ascites in pulmonary arterial hypertension (PAH) in the absence of pre‐existing hepatic dysfunction is usually associated with decompensated right heart failure or cardiac cirrhosis. Ascites in PAH has rarely been associated with intravenous epoprostenol, a synthetic form of the p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schoenberg, Noah C., Ruopp, Nicole F., Parikh, Raj D., Farber, Harrison W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248792/ https://www.ncbi.nlm.nih.gov/pubmed/35795488 http://dx.doi.org/10.1002/pul2.12092

Ejemplares similares

Goiter in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
por: Abughazaleh, Shaadi, et al.
Publicado: (2020)

Stress Cardiomyopathy Precipitated by Withdrawal of Epoprostenol
por: Gionfriddo, William J., et al.
Publicado: (2020)

Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension
por: Abston, Eric, et al.
Publicado: (2020)

Use of Epoprostenol in the Treatment of Pulmonary Arterial Hypertension
por: Mohammadi, Asma, et al.
Publicado: (2021)

Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol
por: Izumi, Keiichi, et al.
Publicado: (2022)

Epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Saito, Yukihiro, et al.
Publicado: (2015)

The Elephant Man Meets Pulmonary Hypertension. A Cautionary Tale
por: Ruopp, Nicole F., et al.
Publicado: (2020)

Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report
por: Alexandre, André, et al.
Publicado: (2023)

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy
por: Timofeev, Julia, et al.
Publicado: (2013)

Case report: Stepwise transition from subcutaneous treprostinil to epoprostenol in high-risk pulmonary arterial hypertension
por: Mori, Ana Laura, et al.
Publicado: (2021)

Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
por: Sitbon, Olivier, et al.
Publicado: (2017)

When “AMBITION” Isn’t Good Enough: Risk Status and Dual Oral Therapy in Pulmonary Arterial Hypertension
por: Schoenberg, Noah C., et al.
Publicado: (2021)

Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
por: Calcaianu, George, et al.
Publicado: (2017)

A Case of Giant Goiter Associated with Airway Stenosis Caused by Long-Term Intravenous Epoprostenol Therapy for Idiopathic Pulmonary Arterial Hypertension
por: Nishiura, Kazuto, et al.
Publicado: (2023)

Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension
por: Lambert, Olivier, et al.
Publicado: (2012)

Epoprostenol discontinuation in patients with pulmonary arterial hypertension: a complex medical and social problem
por: Chebib, Nader, et al.
Publicado: (2017)

Epoprostenol: Exacerbation of thrombocytopenia : case report
Publicado: (2021)

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension
por: Kimura, Mai, et al.
Publicado: (2015)

Alteplase/epoprostenol: Lack of efficacy: case report
Publicado: (2022)

Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Response to “Noninvasive determinants of pulmonary hypertension (PH) in interstitial lung disease (ILD)” by Joseph et al.
por: Parikh, Raj, et al.
Publicado: (2023)

Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension
por: Parikh, Kishan S., et al.
Publicado: (2019)

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series
por: Raina, Amresh, et al.
Publicado: (2017)

Successful use of inhaled epoprostenol as rescue therapy for pediatric ARDS
por: Urich, Alissa, et al.
Publicado: (2020)

Erratum to: Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with a Pulmonary Arterial Hypertension (EPITOME4)
por: Tamura, Yuichi, et al.
Publicado: (2013)

Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension
por: Preston, Ioana R., et al.
Publicado: (2013)

Epoprostenol: Flushing or Erythroderma?
por: Martínez-Martínez, María Luisa, et al.
Publicado: (2013)

Cardiovascular Effect of Epoprostenol and Intravenous Cardiac Drugs for Acute Heart Failure on Canine Pulmonary Hypertension
por: Yuchi, Yunosuke, et al.
Publicado: (2023)

An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report
por: Chida-Nagai, Ayako, et al.
Publicado: (2022)

Pulmonary hypertension secondary to takayasu’s arteritis: management using a combined medical and interventional approach
por: Nitzberg, Matthew, et al.
Publicado: (2020)

Epoprostenol Exposure During Pregnancy
por: Naoum, Emily E., et al.
Publicado: (2023)

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
por: Frantz, Robert P., et al.
Publicado: (2015)

Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection
por: Parikh, Raj, et al.
Publicado: (2022)

Occult catheter rupture causing episodic symptoms in a patient treated with epoprostenol
por: LeVarge, Barbara L., et al.
Publicado: (2017)

Case report: High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease
por: Fukasawa, Yoshie, et al.
Publicado: (2023)

Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children
por: Brown, Anna T., et al.
Publicado: (2012)

Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost—A Multicentre, Retrospective Study
por: Camara, Raquel Paulinetti, et al.
Publicado: (2023)

UTILIZING COMBINATION THERAPY WITH INHALED EPOPROSTENOL AND LOOP DIURETICS IN ACUTE HYPOXIC RESPIRATORY FAILURE FROM COVID-19
por: PINO, MARI-ELENA, et al.
Publicado: (2022)

Management of hospitalized patients with pulmonary arterial hypertension and COVID-19 infection
por: Sahay, Sandeep, et al.
Publicado: (2020)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0sd8ss7qkqhiepueh9hc5msbof